59.13

0.15% -0.09

After Hours: 58.80 -0.33 -0.56%

Veracyte Inc (VCYT)

Overview News Price History Option Chain Financials Discussions Forecast

Veracyte Inc stock is traded at $59.13, with a volume of 2.01M. It is down -0.15% in the last 24 hours and up +15.29% over the past month. Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Previous Close:

$59.22

Open:

$57.06

24h Volume:

2.01M

Relative Volume:

1.70

Market Cap:

$4.72B

Revenue:

$541.74M

Net Income/Loss:

$88.01M

P/E Ratio:

54.44

EPS:

1.0862

Net Cash Flow:

$155.34M

1W Performance:

+3.79%

1M Performance:

+15.29%

6M Performance:

+42.24%

1Y Performance:

+144.14%

1-Day Range:

$57.06

$59.19

1-Week Range:

$55.62

$60.82

52-Week Range:

$22.61

$60.91

Veracyte Inc Stock (VCYT) Company Profile

Name

Veracyte Inc

Sector

Healthcare (1092)

Industry

Diagnostics & Research (49)

Phone

(650) 243-6300

Address

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

755

Twitter

@veracyte

Next Earnings Date

2026-07-30

Latest SEC Filings

VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, NTRA, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCYT Veracyte Inc	59.13	4.73B	541.74M	88.01M	155.34M	1.0862
TMO Thermo Fisher Scientific Inc	532.48	201.86B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	203.83	145.10B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	567.44	45.44B	4.45B	1.10B	1.06B	13.59
NTRA Natera Inc	271.39	38.64B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	131.46	38.44B	7.23B	1.41B	1.09B	4.979

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	Jefferies	Buy
Dec-02-25	Resumed	Morgan Stanley	Underweight
Oct-20-25	Initiated	Canaccord Genuity	Hold
Mar-20-25	Initiated	Craig Hallum	Buy
Dec-05-24	Downgrade	Goldman	Buy → Neutral
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-16-24	Initiated	UBS	Buy
Oct-10-24	Initiated	Guggenheim	Buy
Feb-23-24	Reiterated	Needham	Buy
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Nov-18-21	Resumed	Goldman	Buy
Jun-15-21	Initiated	Raymond James	Outperform
Feb-18-21	Resumed	Needham	Buy
Jan-28-21	Initiated	Truist	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-09-20	Initiated	Morgan Stanley	Underweight
Jul-31-19	Initiated	Lake Street	Buy
Jul-02-19	Initiated	Needham	Buy
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Janney	Buy → Neutral
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-31-17	Resumed	BTIG Research	Buy
Nov-14-16	Resumed	Leerink Partners	Outperform
Dec-18-15	Initiated	Cantor Fitzgerald	Buy
Jun-11-15	Reiterated	Leerink Partners	Outperform
Nov-26-13	Initiated	William Blair	Outperform

View All

Veracyte Inc Stock (VCYT) Latest News

Jul 16, 2026

This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm

Jul 16, 2026

Jul 15, 2026

A Look at Veracyte Inc (VCYT) After 5.1% Gain -- GF Value $38.30 vs Price $59.51 - GuruFocus

Jul 15, 2026

Piper Sandler Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $66 - Moomoo

Jul 15, 2026

Piper Sandler initiates Veracyte stock with overweight rating By Investing.com - Investing.com Nigeria

Jul 15, 2026

Piper Sandler Initiates Veracyte at Overweight With $66 Price Target - marketscreener.com

Jul 15, 2026

VCYT Initiated Coverage by Piper Sandler -- Rating Overweight - GuruFocus

Jul 15, 2026

Jul 14, 2026

CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Raises Target Price to $60 - Moomoo

Jul 14, 2026

VCYT Maintained by Canaccord Genuity -- Price Target Raised to $60 - GuruFocus

Jul 14, 2026

Jul 12, 2026

Here's how much you'd have if you invested $1000 in Veracyte a decade ago - MSN

Jul 12, 2026

Jul 10, 2026

Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Raises Target Price to $47 - Moomoo

Jul 10, 2026

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - BioSpace

Jul 10, 2026

Jul 09, 2026

A Look at Veracyte Inc (VCYT) After 5.5% Gain -- GF Value $38.24 vs Price $59.30 - GuruFocus

Jul 09, 2026

VCYT Maintained by Morgan Stanley -- Price Target Raised to $47. - GuruFocus

Jul 09, 2026

Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - Moomoo

Jul 09, 2026

St. Pete woman seeks $10M in discrimination lawsuit against employer - Business Observer

Jul 09, 2026

Veracyte, Inc. Stock 12‑Month Price Target Raised to $55.8, Implies 1% Downside - TradingView

Jul 09, 2026

Jefferies Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $70 - Moomoo

Jul 09, 2026

Does Veracyte’s (VCYT) Russell Value Index Debut Redefine Its Small-Cap Defensive Narrative? - simplywall.st

Jul 09, 2026

Jul 08, 2026

Veracyte Inc updates investors on breast cancer test coverage. Nasdaq-listed diagnostics group build - ad-hoc-news.de

Jul 08, 2026

All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy - Yahoo Finance

Jul 08, 2026

Jul 07, 2026

Is Veracyte (VCYT) Fully Valued As Insider Selling And Index Additions Draw Attention? - simplywall.st

Jul 07, 2026

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy - AOL.com

Jul 07, 2026